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Abstract
Circulating insulin-like growth factor-one (IGF-I) and IGF binding protein-3 (IGFBP-3) levels
have been associated with common diseases. Although family-based studies suggest that genetic
variation contributes to circulating IGF-I and IGFBP-3 levels, analyses of associations with
multiple IGF-I and IGFBP-3 single nucleotide polymorphisms (SNPs) have been limited,
especially among African Americans. We evaluated 30 IGF-I and 15 IGFBP-3 SNPs and
estimated diplotypes in association with plasma IGF-I and IGFBP-3 among 984 premenopausal
African American and Caucasian women. In both races, IGFBP-3 rs2854746 (Ala32Gly) was
positively associated with plasma IGFBP-3 (CC versus GG mean difference among Caucasians =
631 ng/ml, 95% confidence interval: 398, 864; African Americans = 897 ng/ml, 95% confidence
interval: 656, 1138), and IGFBP-3 diplotypes with the rs2854746 GG genotype had lower mean
IGFBP-3 levels than referent diplotypes with the CG genotype, while IGFBP-3 diplotypes with
the CC genotype had higher mean IGFBP-3 levels. IGFBP-3 rs2854744 (−202 A/C) was in strong
linkage disequilibrium with rs2854746 in Caucasians only, but was associated with plasma
IGFBP-3 in both races. Eight additional IGFBP-3 SNPs were associated with 5% or greater
differences in mean IGFBP-3 levels, with generally consistent associations between races. Twelve
IGF-I SNPs were associated with 10% or greater differences in mean IGF-I levels, but
associations were generally discordant between races. Diplotype associations with plasma IGF-I
did not parallel IGF-I SNP associations. Our study supports that common IGFBP-3 SNPs,
especially rs2854746, influence plasma IGFBP-3 levels among African Americans and
Caucasians, but provides less evidence that IGF-I SNPs affect plasma IGF-I levels.
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Insulin-like growth factor-one (IGF-I), a peptide with structural similarities to insulin, has
been implicated in many biologic processes, including cell cycle regulation, differentiation,
proliferation, hormone secretion, and apoptosis. IGF-binding proteins (IGFBPs) help
regulate the activity of IGFs by influencing their bioavailablity and degradation, and they
may also have independent effects through interactions with cell surface molecules (1,2).
IGFBP-3 binds approximately 90% of circulating IGF-I (3) and has also been reported to
inhibit growth and promote apoptosis (4,5) independent of its effects on IGF-I.
Circulating IGF-I levels, and to a lesser extent IGFBP-3 levels, have been studied in
association with cardiovascular disease, diabetes, and cancer (6-8). Estimates from twin- or
family-based studies suggest that genetic factors may account for up to 50% of the inter-
individual variation in plasma IGF-I levels (9,10) and up to 60% of the variation in plasma
IGFBP-3 levels (9,11). In adults, age is the nongenetic factor most consistently associated
with IGF-I blood levels, with lower levels associated with advancing age (3,12-21). Women
have lower circulating IGF-I (13,16,17,19,21,22) but higher IGFBP-3 levels
(13,16,17,21,22) than men, and two studies have suggested that African American women
have higher circulating IGF-I levels than Caucasian women (17,23).
Our research goal was to investigate relations between IGF-I and IGFBP-3 polymorphisms
and their circulating protein levels among African American and Caucasian women. Prior
analysis of dense single nucleotide polymorphisms (SNPs) and IGF-I and IGFBP-3 levels
among African Americans has been limited to the Multiethnic Cohort Study, which included
a random sample of about 150 African Americans in their IGF SNP analyses (24). We
selected 45 SNPs in IGF-I and IGFBP-3 and examined whether these SNPs and their
estimated diplotypes (paired haplotypes) were associated with plasma IGF-I and IGFBP-3
levels in premenopausal African American and Caucasian women who participated in the
National Institute for Environmental Health Sciences (NIEHS) Uterine Fibroid Study (UFS).
MATERIALS AND METHODS
Study Population
The current study population consisted of 984 premenopausal women (582 African
Americans and 402 Caucasians) that participated in the NIEHS UFS and had available DNA
samples.. The UFS was designed to estimate the prevalence of uterine leiomyomata
(fibroids) among African American and Caucasian women and to evaluate potential
etiologic factors for fibroids. Details of the parent study were previously described (25,26).
Briefly, a random sample of 2,384 George Washington University female health plan
members, aged 35 to 49, was identified for potential enrollment into the parent study
(25,26). The study was approved by Institutional Review Boards at NIEHS and George
Washington University, and the consent form specified use of specimens for genetic
polymorphism analyses.
UFS eligibility criteria were met by 1,786 of the 2,102 women that consented to eligibility
screening. Most ineligible women were excluded because they no longer attended the health
plan clinic where the parent study was based (71%) or they had been misidentified as a
35-49 year-old female (16%). Enrollment occurred from 1996 through 1999. Approximately
20% of eligible women refused participation, resulting in a total of 1,430 participants in the
parent study (26). Demographic characteristics, reproductive history, smoking status, and
alcohol use were assessed from telephone interviews and self-administered questionnaires.
Body weight was measured at the clinic visit.
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We restricted the current study to women who self-identified as African American or
Caucasian (n = 1,323) to facilitate race-specific analyses, and excluded postmenopausal
women because they did not attend the UFS clinic visit for ultrasound screening and blood
collection (n = 178). Race and menopausal status criteria for the current study were met by
1,145 women, and DNA was extracted for 984 of the 1,003 women with blood samples.
Sample Collection and Assays
Fasting blood samples were collected by venipuncture, and plasma was stored at −80°C.
Plasma IGF-I was measured at NIEHS using a double-antibody radioimmunoassay by
extraction method (Nichols Institute Diagnostics, San Juan Capistrano, CA), with a reported
detection limit of 0.06 ng/mL. Plasma IGFBP-3 was measured at NIEHS by a double-
antibody immunoradiometric assay (Diagnostic Systems Laboratories, Inc., Webster, TX),
with a reported detection limit of 0.05 ng/mL The mean inter-assay coefficient of variation
on replicate quality control samples was 8.8% for IGF-I and 4.2% for IGFBP-3.
Genomic DNA was extracted from whole blood using a phenol:chloroform procedure or a
modified salt precipitation protocol (GenQuik Protocol, Orochem Technologies Inc.).
Genetic Polymorphisms
Race-specific tag SNPs in IGF-I and IGFBP-3 were selected using Genome Variation
Server (GVS) software1. We used the Seattle SNPs database as the African American and
Caucasian reference population for IGF-I, and we used the HapMap database for IGFBP-3
because it had not been evaluated by Seattle SNPs. We expanded coverage to include five
kilobases (kb) outside the 5′ and 3′ ends of each gene, specified a pairwise correlation
coefficient (r2) of 0.8 to identify tag SNPs that capture variation across each gene, and
selected tag SNPs with a minor allele frequency (MAF) of at least 5% among the African
American or Caucasian reference populations. The GVS software identified 29 tag SNPs for
IGF-I and 12 tag SNPs for IGFBP-3 that met these criteria. In addition, we selected five
SNPs a priori including one nonsynonymous IGF-I SNP (rs17884626), one synonymous
IGF-I SNP (rs3729846), two nonsynonymous IGFBP-3 SNPs (rs2854746, rs9282734), and
an IGFBP-3 promoter SNP (rs2854744, −202 A/C) previously evaluated in association with
circulating IGFBP-3 levels and health outcomes (24,27-35).
Genotyping was performed using the TaqMan genotyping approach (36-38) at the
Mammalian Genotyping Core, Lineberger Comprehensive Cancer Center (Chapel Hill, NC).
Allele-specific oligonucleotide probes for 39 selected SNPs were purchased from Applied
Biosystems (ABI; Foster City, CA) “TaqMan® Validated and Coding SNP or Pre-Designed
SNP Genotyping Assays”. ABI attempted to develop custom assays for the 6 remaining
SNPs through their “Custom TaqMan® SNP Genotyping Assays” service. Two IGF-I tag
SNPs were dropped from analyses, including one for which a custom assay could not be
developed, and one with a pre-designed assay that did not meet ABI technical specifications.
In addition, we genotyped an alternate IGF-I tag SNP to replace one that was inconsistent
with Hardy-Weinberg equilibrium (HWE) in our African American population. We
genotyped 30 IGF-I and 15 IGFBP-3 SNPs (Supplemental Figures 1-2).
PCR amplification was performed on an ABI GeneAmp® PCR System 9700 thermal cycler
with dual 384-well-blocks, and endpoint plates were read using the ABI 7900HT system.
Fluorescent VIC and 6-FAM reporter dyes differentiated wild type and variant alleles. The
Sequence Detection System (SDS) 2.3 software automatically called alleles; experienced
1Genome Variation Server (GVS) Version 1.04. Seattle (WA): Seattle SNPs Program for Genomic Applications (PGA). [updated
2006 June 16; cited 2006 July 9]. Available from: http://gvs.gs.washington.edu/GVS/
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operators reviewed the software output. The samples’ DNA concentrations were validated
using a NanoDrop® ND-1000 Spectrophotometer prior to dilution to five ng/ul using DNA
grade sterile water. Samples were placed into 96-well microtiter plates with two blank and
two known DNA standard (Control DNA CEPH Individual 1347-02, ABI) samples, and
were subsequently aliquoted into 384-well PCR plates. Quality control measures included
blinded genotyping of 28 duplicate samples representing 22 women, which produced
concordant results for all samples. The overall call rate was 98.8%, and only five women
had less than 50% of complete allele calls for the 45 SNPs assayed. We confirmed that SNP
genotype frequencies were consistent with HWE within each racial group using the exact
test statistic with one degree of freedom (alpha = 0.01) (39).
Diplotype Estimation
To simultaneously evaluate associations between linked polymorphic loci and their plasma
protein levels, we estimated race-specific IGF-I and IGFBP-3 diplotypes. SNPs were
excluded from race-specific diplotype analyses if their MAF in our study population was
below 5% for tag SNPs or below 3% for a priori SNPs within the racial group being
evaluated. Women missing genotype data for more than 50% of the SNPs considered for
diplotype analyses within a gene were excluded from diplotype estimation for that gene (one
Caucasian and three African Americans for IGFBP-3, three Caucasians and two African
Americans for IGF-I). We examined race-specific linkage disequilibrium (LD) patterns
using Haploview software (40) to identify SNPs in each gene that could be combined for
estimating diplotypes. First, we identified LD blocks consisting of individual SNPs (with
MAF at least 5%) in strong LD (95% of pairwise SNP comparisons with one-sided 95%
confidence intervals (CI) for D’ within 0.70 to 0.98) (41). Next, we used the Tagger
approach (42) in Haploview to identify pairs of redundant SNPs in strong LD (pairwise r2
values of at least 0.8), and excluded one member of each redundant pair from diplotype
estimation unless both SNPs were selected a priori. Race-specific pairwise r2 values are
available for IGFBP-3 and IGF-I SNPs in Supplemental Tables 1-4.
Race-specific diplotypes representing defined groups of SNPs in each gene were estimated
using PHASE version 2.1 (43,44), which allocates the most likely diplotype to each subject,
with the prior assumption that frequently observed haplotypes with less ambiguity due to
homozygosity are more probable. PHASE also provides a posterior probability estimate that
expresses the uncertainty associated with each diplotype assignment. To reduce the number
of race-specific diplotype groups for analyses, we combined single (unlinked) SNPs with an
adjacent LD block and adjacent LD blocks with each other, if the larger groups resulted in
diplotypes estimated with at least 90% certainty (posterior probability) for at least 90% of
observations. Otherwise, diplotype groups were composed of individual SNPs or LD blocks.
We assigned women to their most probable diplotype for each group; however, if their most
probable diplotype had a posterior probability below 90%, we classified their diplotype
group as missing.
Statistical Analyses
Primary statistical analyses were stratified by race and conducted using SAS v9.1 (SAS
Institute Inc., Cary, NC). We used linear regression to estimate associations between IGF-I
and IGFBP-3 SNP variants and their respective circulating protein levels. Estimated
associations are unadjusted since there are no known factors other than race that would
predict both plasma levels and SNP variants.
For individual SNP analyses, we generally used codominant inheritance models that
estimated associations separately for heterozygous and homozygous variants relative to the
referent genotype, which was defined as the most common race-specific homozygous
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genotype in our study population. However, when there were 10 or fewer women with the
homozygous variant genotype, we used a dominant model that combined heterozygous and
homozygous variants for comparison with the referent genotype. We evaluated the
concordance of estimated associations between races (i.e., the difference in mean differences
between races) (Supplemental Tables 5-6) by combining the data for both races and
applying linear regression models that included multiplicative genotype by race interaction
terms with separate parameters for race and genotypes.
To estimate diplotype associations with plasma IGF-I or IGFBP-3 levels, we used separate
race-specific models for each diplotype group, with the most common diplotype as the
reference category. Diplotypes assigned to 5 or fewer women were combined into one “rare
diplotype” category. We used an empirical-Bayes method of information-weighted
averaging to enhance the validity and precision of regression estimates (45). Specifically, we
assumed a prior mean of 0, since we had no prior information to group diplotypes according
to the anticipated direction of associations with plasma levels. We specified a prior variance
corresponding to +/− one standard deviation of the mean plasma levels (2*standard
deviation/3.92)2 of IGF-I (prior variances: African Americans, 1,419; Caucasians, 901) and
IGFBP-3 (prior variances: African Americans, 186,819; Caucasians, 174,161). This method
shrinks regression estimates toward the prior mean such that imprecise estimates based on
smaller numbers of observations are shifted further toward the prior mean than more precise
estimates. We applied the shrinkage estimator for each diplotype and report posterior
medians (50th percentile of the posterior probability distribution) and 95% posterior limits
(2.5th and 97.5th percentiles of the posterior probability distribution). Regression estimates




Race-specific mean plasma IGF1 and IGFBP-3 levels and other characteristics of the study
population are displayed in Table 1. African Americans were less likely than Caucasians to
have a college or graduate degree (33% vs. 87%), to report regular alcohol consumption
(42% vs. 78%), or to be nulliparous at UFS enrollment (21% vs. 59%). African Americans
were more likely than Caucasians to be overweight or obese (75% vs. 41%) and to report
current smoking (30% vs. 8%). Few women were currently taking oral contraceptives.
IGFBP-3
For plasma IGFBP-3, we focused on estimated differences in mean levels of at least 200 ng/
ml for index genotypes or diplotypes relative to the referent (i.e., roughly +/− 5% of the
estimated mean level for the referent genotype or diplotype, which ranged from 3798 to
4693 ng/ml). We disregarded imprecise associations with rare SNPs having 10 or fewer
observations with heterozygous and homozygous variants.
SNP Analyses—The variants for 10 IGFBP-3 SNPs (rs903889, rs924140, rs2854744,
rs2854746, rs2471551, rs3110697, rs2453840, rs2453839, rs2270628, rs12671457) were
associated with differences of 200 ng/ml or greater in estimated mean IGFBP-3 levels
among at least one racial group when compared with referent genotypes (Table 2). In both
races, variants for rs924140, rs2854744, and rs2854746 were associated with differences in
plasma IGFBP-3 levels of approximately 500-900 ng/ml for homozygous variants and
approximately 300-500 ng/ml for heterozygotes relative to the estimated mean levels for
referent genotypes. Pairwise r2 values for all three SNPs were at least 0.8 among
Caucasians, indicating strong LD in our study population. Among African Americans,
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rs924140 and rs2854744 were also in strong LD (r2 = 0.82); however, neither SNP was in
LD with rs2854746 (r2 = 0.30-0.34). In both races, rs3110697 was also in moderate LD with
rs924140 and rs2854744 (r2 = 0.55-0.65), and its variants were inversely associated with
plasma IGFBP-3 (about 430 ng/ml lower in Caucasians and 550 ng/ml lower in African
Americans with the AA genotype, with smaller differences estimated for the AG genotype
relative to those with the GG genotype). Plasma IGFBP-3 was also inversely associated with
rs2471551 variants among African Americans (460ng/ml lower for the CC genotype and
260ng/ml lower for the CG genotype relative to the GG genotype).
Inverse associations between homozygous variants for five SNPs (rs903889, rs2471551,
rs2453840, rs2453839, rs2270628) and plasma IGFBP-3 were noted among Caucasians, but
estimates were relatively imprecise since they were based on fewer than 25 observations.
Two of these SNPS, rs2453840 and rs2453839, were in strong LD (r2 = 0.87) among
Caucasians. Among African Americans, combined homozygous and heterozygous variants
for rs2453840 and rs12671457 were positively and inversely associated with plasma
IGFBP-3 respectively, with differences of about 200 ng/ml relative to referent genotypes.
SNP associations with plasma IGFBP-3 showed little evidence of discordance by race based
on estimated African American versus Caucasian differences in these associations
(Supplemental Table 5). Three possible exceptions were rs2854746 (CC versus GG
genotype difference between races, 266; 95% CI: −70, 602), rs2453840 (AA and AC versus
CC genotype difference between races, 298; 95% CI: 45, 551) and rs2270628 (TT versus
CC genotype difference between races, 400; 95% CI: −88, 888). However, estimated
differences in mean differences between races, especially for homozygous variants, were
fairly imprecise.
Diplotype Analyses—Among Caucasians, three LD blocks accounted for 10 of 12
IGFBP-3 SNPs included in diplotype analyses, with two SNPs outside LD blocks. After
excluding two redundant IGFBP-3 SNPs (r2 ≥ 0.8), we created two diplotype groups, as
described previously (Table 2), and completed diplotype estimation in each group for 93%
to 98% of Caucasians. Overall, we estimated 48 unique diplotypes, including 20 classified
as rare based on assignment to five or fewer women.
Among African Americans, four LD blocks accounted for 11 of 14 IGFBP-3 SNPs included
in diplotype analyses, with three SNPs outside LD blocks. After excluding one redundant
IGFBP-3 SNP (r2 ≥ 0.8), we created three diplotype groups (Table 2), and completed
diplotype estimation in each group for 94% to 99% of African Americans. Overall, we
estimated 71 unique diplotypes, which included 33 rare diplotypes.
Six Caucasian IGFBP-3 group 1 diplotypes (1a-1f) were associated with decreases of 200
ng/ml or greater in estimated mean IGFBP-3 levels relative to the referent diplotype (Figure
1). All six diplotypes (1a-1f) included the GG genotype for rs2854746 (3rd diplotype
position), and five diplotypes (1a, 1b, 1d-1f) included the CC genotype for rs2854744 (2nd
diplotype position). The only two Caucasian IGFBP-3 group 1 diplotypes (1m, 1n) with the
CC genotype for rs2854746 were positively associated with plasma IGFBP-3.
Ten African American IGFBP-3 group 1 diplotypes (1a-1j) were inversely associated with
plasma IGFBP-3 relative to the referent diplotype, including eight (1a-1h) with the GG
genotype for rs2854746 (3rd diplotype position), three (1a, 1c, 1e) with the CC genotype for
rs2854744 (2nd position), and the only one (1c) with the CC genotype for rs2471551 (4th
diplotype position) (Figure 1). In addition, the only African American IGFBP-3 group 1
diplotype (1r) with the CC genotype for rs2854746 was positively associated with plasma
IGFBP-3. One African American IGFBP-3 group 2 diplotype (2a) and two group 3
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diplotypes (3a, 3b) were associated with lower mean IGFBP-3 levels relative to the referent
diplotype while one group 3 diplotype (3l) was associated with a higher mean level.
IGF-I
For plasma IGF-I, we focused on estimated differences in mean levels of at least 16-18 ng/
ml for index genotypes or diplotypes relative to the referent (i.e., about +/− 10% of the
estimated mean level for the referent genotype or diplotype, which ranged from 158 to 176
ng/ml). We did not consider imprecise associations with rare SNPs having 10 or fewer
observations with heterozygous and homozygous variants.
SNP Analyses—Among Caucasians, homozygous variants for two common IGF-I SNPs
(rs1520220, rs6214) and variants for five rare (MAF < 5%) IGF-I SNPs (rs5742612,
rs5742614, rs5742657, rs5742692, rs3730204) were associated with 10% or greater
differences in estimated mean IGF-I levels relative to referent genotypes (Table 3).
However, with the exception of the positive association with the rs6214 TT genotype,
estimates were relatively imprecise due to 30 or fewer observations with variants. None of
the IGF-I SNPs noted above were in LD (r2 < 0.4), except for strong LD between rs5742657
and rs5742692 (r2 = 0.94).
Among African Americans, combined homozygous and heterozygous variants for three rare
(MAF < 5%) IGF-I SNPs (rs2033178, rs17727841, rs11111262) were associated with
differences of approximately 15% to 25% relative to estimated mean IGF-I levels for the
referent genotypes although the association with the rs11111262 variants was based on
fewer than 30 observations (Table 3). In addition, variants for two more common IGF-I
SNPs (rs6219, rs2946834) were associated with 10% increases in estimated mean IGF-I
levels relative to referent genotypes. Of the five IGF-I SNPs noted above, only rs17727841
and rs11111262 were in moderate LD (r2 = 0.56).
Based on models that included interaction terms with race, estimated mean differences in
IGF-I levels for 13 IGF-I SNP variants varied by at least 16 ng/ml in African Americans
versus Caucasians (Supplemental Table 6). These included four SNPs within or near exon 4,
which was where plasma IGF-I associations were predominantly noted: rs11111262 (AG/
AA versus GG genotype difference between races, 44; 95% CI: 13, 75), rs1520220 (GG
versus CC genotype difference between races, 43; 95% CI: 1, 85), rs6219 (CT/TT versus CC
genotype difference between races, 21; 95% CI: −1, 44), and rs2946834 (AA versus GG
genotype difference between races, 24; 95% CI: −4, 52). However, estimated differences in
mean differences between races were relatively imprecise.
Diplotype Analyses—Among Caucasians, three LD blocks accounted for 15 of 17 IGF-I
SNPs included in diplotype analyses, with two SNPs outside LD blocks. After excluding six
redundant IGF-I SNPs (r2 ≥ 0.8), we created four diplotype groups (Table 3) and completed
diplotype estimation in each group for 97% to 99% of Caucasians. Overall, we estimated 40
unique diplotypes, including 13 classified as rare based on assignment to five or fewer
women.
Among African Americans, four LD blocks accounted for 16 of 20 IGF-I SNPs included in
diplotype analyses, with four SNPs outside LD blocks. After excluding six redundant IGF-I
SNPs (r2 ≥ 0.8), we created four diplotype groups (Table 3) and completed diplotype
estimation in each group for 95% to 99% of African Americans. Overall, we estimated 73
unique diplotypes, which included 25 rare diplotypes.
Five Caucasian IGF-I group 3 diplotypes (3f-3j) were associated with 10% or greater
increases in estimated mean IGF-I levels relative to the referent diplotype, although two
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estimates (3g, 3j) were relatively imprecise due to few observations with either diplotype
(Figure 2). One African American IGF-I group 1 diplotype (1g) and one group 4 diplotype
(4e) were associated with increases of 15% to 20% in mean IGF-I levels relative to the
referent diplotypes. In addition, one African American IGF-I group 1 diplotype (1a), four
group 2 diplotypes (2a, 2m-2o) and two group 3 diplotypes (3a, 3q) were associated with
10% or greater differences in mean IGF-I levels compared to the referent diplotypes,
although estimates were fairly imprecise due to small numbers of observations. IGF-I
diplotype associations with plasma IGF-I did not parallel SNP associations, unlike
associations between IGFBP-3 diplotypes and plasma IGFBP-3.
DISCUSSION
Evidence of a causal association was strongest for the nonsynonymous IGFBP-3 SNP,
rs2854746, with plasma IGFBP-3 levels. In both races, the rs2854746 CC genotype was
associated with higher mean IGFBP-3 levels than were estimated for the GG genotype,
while mean levels for the CG genotype were intermediate. In addition, IGFBP-3 diplotypes
with the rs2854746 GG genotype had consistently lower mean IGFBP-3 levels than those
estimated for referent diplotypes with the CG genotype in both races, while IGFBP-3
diplotypes with the CC genotype had higher mean IGFBP-3 levels.
Biologic evidence supports a causal relation of rs2854746 with plasma IGFBP-3, since this
SNP results in an amino acid change from alanine to glycine, and protein sequence analysis
suggests that the amino acid coded by rs2854746 is within the region of IGFBP-3
responsible for IGF-I binding (46). The Multiethnic Cohort Study, a large study of
Caucasian women from the Breast and Prostate Cancer Cohort Consortium, and a small
Caucasian study reported associations between rs2854746 and plasma IGFBP-3 that were
consistent with our findings (24,35,47). Therefore, individual rs2854746 associations and
correspondence with IGFBP-3 diplotype findings among both races, in addition to biologic
evidence, support a causal association between rs2854746 and plasma IGFBP-3.
Other genetic studies of circulating IGFBP-3 have not evaluated rs2854746, but several have
examined the IGFBP-3 promoter SNP, rs2854744 (−202 A/C), predominantly among
Caucasians. Several studies reported higher mean IGFBP-3 levels among individuals with
the AA genotype compared to those with the CC genotype, and intermediate levels among
those with the AC genotype (24,27-35). We also noted increases in mean IGFBP-3 levels for
rs2854744 AA versus CC genotypes in both races although plasma IGFBP-3 associations
with diplotypes that included rs2854744 variants were not as consistent as those with
diplotypes that included rs2854746 variants, especially among African Americans.
Consistent with the Multiethnic Cohort Study (24), we noted strong LD between rs2854744
and rs2854746 (r2 = 0.82) in Caucasians that may partly explain associations between
rs2854744 variants and plasma IGFBP-3, although these two SNPs were not in LD among
African Americans (r2 = 0.34). Deal, et al. reported that promoter activity was increased in
vitro in association with the rs2854744 A allele (28), which suggests that rs2854744 may
influence circulating IGFBP-3 levels independent of its association with rs2854746. Similar
to our study, four studies reported decreased IGFBP-3 levels in association with rs3110697
variants relative to the referent genotype (24,33-35), and the Multiethnic Cohort Study also
reported that rs3110697 was not in strong LD with rs2854744 or rs2854746 among both
races (24).
We also reported consistent inverse associations between IGFBP-3 rs2471551 variants and
plasma IGFBP-3 among both races. This SNP has potential functional relevance as it is
located near a splice site (< 20 base pairs from the 5′ side of exon 2). Canzian, et al. and
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Diorio, et al. reported that the rs2471551 CC genotype was inversely associated with
circulating IGFBP-3 relative to the GG genotype within Caucasian women (27,34).
Many epidemiologic studies of IGF-I have focused on the dinucleotide CA repeat
polymorphism (position −969) located in the promoter approximately one kb upstream of
the transcription site; however, associations between CA repeat polymorphisms and
circulating IGF-I levels have been inconsistent (23,30,31,48-55). Methodological
differences in the categorization of repeat genotypes and the potential for substantial
misclassification during genotyping make it difficult to compare results across studies (56).
Although we did not evaluate this repeat polymorphism, we evaluated three IGF-I SNPs
within five kb of the 5′ and 3′ ends of the gene, and found that two were associated with
10% or greater differences in mean IGF-I levels (rs5742612 among Caucasians and
rs2946834 among African Americans). However, Diorio, et al. reported no association
between rs5742612 variants and plasma IGF-I within their study of Caucasian women (34).
There have been no reports of LD between the IGF-I repeat polymorphism and any of the
SNPs in our study, with the exception of rs5742612 in a Chinese population (57). Due to
rs5742612 MAF differences for Chinese versus African Americans or Caucasians, it is
unlikely that rs5742612 would be in LD with the repeat polymorphism in our study
population.
We estimated higher mean IGF-I levels in association with the rs6214 TT versus CC
genotypes among Caucasians. In contrast, Al-Zahrani, et al. and Canzian, et al. reported no
association between rs6214 and circulating IGF-I within predominantly Caucasian study
populations (27,29). Consistent with the Multiethnic Cohort Study (24), we found no
association between rs35767 and plasma IGF-I in either racial group. However, Canzian, et
al. and Patel, et al. noted associations between rs35767 and circulating IGF-I in large studies
of Caucasian women (27,35). We also noted an inverse association between plasma IGF-I
and the rs1520220 GG versus CC genotypes among Caucasians and a positive association
with rs2946834 AA versus GG genotypes among African Americans, although estimated
differences in race-specific associations may not be meaningful given their imprecision. Al-
Zahrani, et al. and Patel, et al. reported higher mean IGF-I levels in association with
rs1520220 and rs2946834 variants relative to referent genotypes in Caucasian women
(29,35), although Al-Zahrani, et al. reported that only the association with rs1520220
variants remained after adjustment for rs2946834 (29). However, rs1520220 and rs2946834
variants were not associated with plasma IGF-I in the Multiethnic Cohort Study (24), and
Diorio, et al. reported no association with rs1520220 variants (34). Comparison of race-
specific IGF-I SNP and diplotype associations with plasma IGF-I suggests that an untyped
functional polymorphism may lie near or within the untranslated region of exon 4, but we
could not identify this polymorphism from evaluation of the literature.
A strength of this study is that participants were randomly selected from health plan
membership roles, with response rates of about 80% for both races. However, selection bias
could exist if eligible women excluded from our analysis differed from the women that were
included with respect to their plasma IGF-I or IGFBP-3 levels or genotypes. In particular,
161 (14%) eligible women lacked DNA for genotyping primarily because of no available
blood samples, which included a slightly greater proportion of missing African Americans
(16%) than Caucasians (12%).
The use of diplotype analysis strengthened our study as it provided support for detecting
which SNPs may be causally associated with circulating protein levels, and it assisted with
identifying regions where untyped SNPs that influence circulating protein levels may reside.
Diplotype associations were unlikely to be biased by the exclusion of women who had
diplotypes estimated with low certainty (posterior probability < 90%), since only 1% to 7%
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of women were excluded from analyses of each diplotype group based on this criterion. Rare
diplotypes were assigned with lower certainty, as the PHASE software assumes that
frequently observed haplotypes with less ambiguity are more probable. We combined rare
diplotypes assigned to five or fewer women into a single category, but we did not interpret
associations with these categories due to their heterogeneity.
Despite restricting our study to Caucasians and African Americans and stratifying analyses
by race, population stratification within each racial group is a potential limitation of our
study. Population stratification is more likely to bias results within African Americans due
to their inherently greater admixture than Caucasians. However, the degree of bias depends
on the number of ethnicities and the range of their genotype frequencies within the racial
group, in addition to the true magnitude of genotype association with the outcome (58-60).
Concordance between races for IGFBP-3 SNP findings suggests that population
stratification was less likely to bias these results although population stratification within
races may still be present. However, population stratification within races may have more
strongly influenced the IGF-I SNP findings as there were notable differences between races.
Our use of information-weighted averaging intentionally biased estimates of associations
with race-specific diplotypes towards the null since we assumed a null value for the prior
mean. However, this approach increased the precision of estimates, particularly for
diplotypes assigned to small numbers of women. Despite the increase in bias with estimating
posterior medians, a reduction in the overall mean square error based on a greater decrease
in variance of estimates has been shown with simulation studies and an occupational cohort
study (61). Although we did not interpret our results based on hypothesis tests, this approach
also reduces the likelihood of type I error with multiple comparisons (62-64).
The parent study obtained only one measurement of plasma IGF-I and IGFBP-3 from study
participants; however, the Nurses’ Health Study reported high correlations (> 0.8) for
plasma IGF-I and IGFBP-3 measurements in premenopausal women that were repeated over
time (65). Age and sex are strong predictors of circulating IGF-I and IGFBP-3; however,
these factors were unlikely to influence our results since our study population was restricted
to premenopausal women within a 15-year age range (35 to 49 years), and adjusting for age
did not affect results (data not shown).
A major strength of our study was the large number of African American participants, since
previous research has mostly focused on relations between IGF-I and IGFBP-3 SNPs and
their circulating protein levels in Caucasians. Because African Americans have more genetic
heterogeneity than Caucasians, the frequency of etiologically relevant SNPs may differ, and
may at least partly explain racial disparities in the burden of cancer and cardiovascular
disease. Therefore, assessing IGF-I and IGFBP-3 SNPs that predict circulating IGF-I and
IGFBP-3 levels will improve our understanding of the biological role of IGF-I and IGFBP-3
in the etiology of common diseases.
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Refer to Web version on PubMed Central for supplementary material.
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Estimated differences from mean plasma IGFBP-3 levels associated with IGFBP-3
diplotypes for premenopausal Caucasian and African American women, based on race-
specific linear regression models of each IGFBP-3 diplotype group on plasma IGFBP-3
levels. Posterior medians (95% posterior limits) were estimated using empirical-Bayes
method of information-weighted averaging by assuming a prior mean of 0 and a prior
variance (Caucasians: 174,161; African Americans: 186,819) corresponding to one standard
deviation of mean plasma IGFBP-3 (2*standard deviation/3.92)2. For Caucasian models,
Group 1 includes N=370, and Group 2 includes N=391. For African American models,
Group 1 includes N = 539, Group 2 includes N = 563, and Group 3 includes N = 547. The
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shaded area indicates ±200 ng/ml, which is approximately 5% of the mean plasma IGFBP-3
levels (Caucasians: Group 1 = 4661 ng/ml, Group 2 = 4587 ng/ml; African Americans:
Group 1 = 4327 ng/ml, Group 2 = 4060 ng/ml, Group 3 = 4106 ng/ml) for each referent
diplotype.
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Estimated differences from mean plasma IGF-I levels associated with IGF-I diplotypes for
premenopausal Caucasian and African American women, based on race-specific linear
regression models of each IGF-I diplotype group on plasma IGF-I levels. Posterior medians
(95% posterior limits) were estimated using empirical-Bayes method of information-
weighted averaging by assuming a prior mean of 0 and a prior variance (Caucasians: 901;
African Americans: 1,419) corresponding to one standard deviation of mean plasma IGF-I
(2*standard deviation/3.92)2. For Caucasian models, Group 1 includes N = 394, Group 2
includes N = 393, Group 3 includes N = 389, and Group 4 includes N = 393. For African
American models, Group 1 includes N = 565, Group 2 includes N=558, Group 3 includes
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N=545, and Group 4 includes N=565. The shaded area indicates ±10% of the mean plasma
IGF-I levels (Caucasians: Group 1 = 171 ng/ml, Group 2 = 173 ng/ml, Group 3 = 165 ng/ml,
Group 4 = 172 ng/ml; African Americans: Group 1 = 166 ng/ml, Group 2 = 162 ng/ml,
Group 3 = 166 ng/ml, Group 4 = 162 ng/ml) for each referent diplotype.
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Table 1
Characteristics of premenopausal Caucasian and African American women with genotype information from









 35-39 137 (34.1) 219 (37.6)
 40-44 135 (33.6) 205 (35.2)
 45+ 130 (32.3) 158 (27.1)
Education
 High school 12 (3.0) 121 (20.8)*
 Some postsecondary 33 (8.2) 265 (45.5)
 College degree 133 (33.1) 123 (21.1)
 Graduate degree 217 (54.0) 68 (11.7)
 Missing 7 (1.7) 5 (0.9)
Current oral contraceptives† 37 (9.2) 28 (4.8)
Parity
 0 236 (58.7) 120 (20.6)
 1 54 (13.4) 134 (23.0)
 2 91 (22.6) 194 (33.3)
 3+ 21 (5.2) 134 (23.0)
Body mass index
 Under- normal weight 236 (58.7) 147 (25.3)
 Overweight (25-<30) 95 (23.6) 178 (30.6)
 Obese (30+) 71 (17.7) 257 (44.2)
Smoking status
 Current smoker 31 (7.7) 172 (29.6)
 Former smoker 139 (34.6) 133 (22.9)
 Never smoked 232 (57.7) 277 (47.6)
Alcohol intake (past year)
 <0.5 drinks/week 60 (14.9) 300 (51.5)
 ≥0.5 drinks/week 314 (78.1) 245 (42.1)
 Missing 28 (7.0) 37 (6.4)
Mean (SD) Mean (SD)
Plasma IGF-I (ng/ml)† 172 (58.7) 165 (74.0)
Plasma IGFBP-3 (ng/ml)† 4524 (822.3) 4085 (859.7)
*
Includes 11 women with less than high school education.
†
N missing: oral contraceptives: 3 Caucasians, 4 African Americans; IGF-I and IGFBP-3: 1 Caucasian, 8 African Americans.
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